proxyvotesnow.com

Home › Companies › Cytek Biosciences, Inc. › 2025-2026

Cytek Biosciences, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Cytek Biosciences, Inc.’s Form 8-K, filed 2026-06-16 (Item 5.07 on EDGAR). Page generated 04 October 2026.

  • 5Ballot items
  • 177Asset managers
  • 1,236Fund votes
  • 2026-06-10Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Cytek Biosciences, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Cytek Biosciences, Inc.

These tallies are Cytek Biosciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-16 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Cytek Biosciences, Inc. — official shareholder meeting results, meeting held 2026-06-10
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Vera Imper, Ph.D. 64,769,976---- 20,723,47725,668,037 Majority: yes
Elect Director: Glenn P. Muir 79,599,103---- 5,894,35025,668,037 Majority: yes
Elect Director: Ming Yan, Ph.D. 76,741,063---- 8,752,39025,668,037 Majority: yes
Proposal 2: Executive Compensation. On a non-binding, advisory basis, the compensation paid to the Company's named executive officers for the year ended December 31, 2025 was approved based on the following results of voting: 84,794,380677,86121,212 --25,668,037 Passed
Proposal 3: Ratification of the Selection of Independent Registered Public Accounting Firm. The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on 110,533,253479,883148,354 ---- Majority: yes

Source: Cytek Biosciences, Inc., Form 8-K, filed with the SEC on 2026-06-16 — read the filing on EDGAR.

How asset managers voted at the Cytek Biosciences, Inc. 2025-2026 meeting

Each item below shows how the 177 asset managers that disclosed a Cytek Biosciences, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. To approve, on a non-binding, advisory basis, the compensation of our named executive officers for the year ended December 31, 2025, as set forth in our proxy statement.

SECTION 14A SAY-ON-PAY VOTESCompany result: Passed

Combines 5 wordings of this item as funds reported it.

99.2% Passed · of votes cast

FOR 99.2%
FOR: 84,794,380AGAINST: 677,861

Cytek Biosciences, Inc.’s own tally for this item (“Proposal 2: Executive Compensation. On a non-binding, advisory basis, the compensation paid to the Company's named executive officers for the year ended December 31, 2025 was approved based on the following results of vo”): 84,794,380 for, 677,861 against — passed, per its Form 8-K filed 2026-06-16 (Item 5.07). Of all 129,142,587 outstanding shares: 66% for, 0.6% against (66% of the company cast a for/against vote).

The 176 asset managers below cast 99.0% of the shares they voted on this item FOR (74,779,896 for, 753,189 against).

FOR 99%
FOR: 74,779,896 (99.0%)AGAINST: 753,189 (1.0%)ABSTAIN: 11,449 (0.0%)
Largest asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of our named executive officers for the year en” at Cytek Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock16,204,8980 00For
Vanguard8,090,8124 00For
Topline Capital Management, LLC7,141,1840 00For
HHLR ADVISORS, LTD.6,657,0300 00For
Boston Partners5,665,8380 00For
State Street3,394,6520 00For
GEODE CAPITAL MANAGEMENT, LLC2,775,4360 00For
Fidelity2,744,7760 00For
TRUST FOR PROFESSIONAL MANAGERS2,017,8470 00For
Charles Schwab2,017,5560 00For
Russell Investments1,697,3390 00For
Royce1,642,3680 00For
BROWN CAPITAL MANAGEMENT LLC1,394,6980 00For
Goldman Sachs1,188,2320 00For
Dimensional1,043,5750 00For
Brown Capital Management Mutual Funds973,7070 00For
RBB FUND, INC.920,0360 00For
Northern Trust803,4220 00For
MELLON INVESTMENTS Corp633,6390 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC598,6530 00For
American Century0563,344 00Against
PRINCIPAL GLOBAL INVESTORS534,0820 00For
Invesco361,5300 00For
BANK OF AMERICA NA315,2130 00For
Equitable283,0940 00For

Showing the 25 largest of 176 asset managers. See all 176 in the interactive database.

2. TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

FOR 99.5%
FOR: 110,533,253AGAINST: 479,883

Cytek Biosciences, Inc.’s own tally for this item (“Proposal 3: Ratification of the Selection of Independent Registered Public Accounting Firm. The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending”): 110,533,253 for, 479,883 against, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 129,142,587 outstanding shares: 86% for, 0.4% against (86% of the company cast a for/against vote).

The 58 asset managers below cast 99.9% of the shares they voted on this item FOR (35,240,368 for, 2,641 against).

FOR 99.9%
FOR: 35,240,368 (100.0%)AGAINST: 2,641 (0.0%)
Largest asset managers voting on “TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE ” at Cytek Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock12,354,6590 00For
Vanguard7,318,1952 00For
Fidelity2,553,6040 00For
TRUST FOR PROFESSIONAL MANAGERS2,017,8470 00For
Royce1,628,0950 00For
State Street1,213,114648 00For
Brown Capital Management Mutual Funds973,7070 00For
Charles Schwab911,2030 00For
Goldman Sachs845,0790 00For
RBB FUND, INC.801,2190 00For
Dimensional785,1500 00For
Russell Investments597,7860 00For
Equitable283,0940 00For
American Century281,5780 00For
TIAA242,3550 00For
QUANTITATIVE MASTER SERIES LLC199,1550 00For
Jackson National194,8090 00For
Columbia Threadneedle167,5570 00For
Lincoln Financial167,1070 00For
JPMorgan157,6210 00For
Invesco151,3810 00For
Voya134,5980 00For
Prudential/PGIM109,5520 00For
AIG/SunAmerica95,5720 00For
BNY Mellon93,5160 00For

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

3. To elect our three Class II director nominees, Vera Imper, Ph.D., Glenn P. Muir, and Ming Yan, Ph.D., each to serve a three-year term expiring at our 2029 annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation, or removal: Glenn P. Muir

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 79,599,103WITHHELD: 5,894,350

Cytek Biosciences, Inc.’s own tally for this item (“Elect Director: Glenn P. Muir”): 79,599,103 for, 5,894,350 withheld, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 129,142,587 outstanding shares: 62% for, 5% withheld (66% of the company cast a for/withheld vote).

The 57 asset managers below cast 100% of the shares they voted on this item FOR (32,415,372 for, 0 against).

FOR 92%8%
FOR: 32,415,372 (92.0%)ABSTAIN: 2,819,128 (8.0%)
Largest asset managers voting on “To elect our three Class II director nominees, Vera Imper, Ph.D., Glenn P. Muir, and Ming Yan, Ph.D., each to ” at Cytek Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock12,354,6590 00For
Vanguard7,318,1360 620For
Fidelity2,553,6040 00For
TRUST FOR PROFESSIONAL MANAGERS00 2,017,8470Abstain
Royce1,628,0950 00For
State Street1,213,7620 00For
Brown Capital Management Mutual Funds973,7070 00For
Charles Schwab911,2030 00For
Goldman Sachs845,0790 00For
RBB FUND, INC.00 801,2190Abstain
Dimensional785,1500 00For
Russell Investments597,7860 00For
Equitable283,0940 00For
American Century281,5780 00For
TIAA242,3550 00For
QUANTITATIVE MASTER SERIES LLC199,1550 00For
Jackson National194,8090 00For
Columbia Threadneedle167,5570 00For
Lincoln Financial167,1070 00For
JPMorgan157,6210 00For
Invesco151,3810 00For
Voya134,5980 00For
Prudential/PGIM109,5520 00For
AIG/SunAmerica95,5720 00For
BNY Mellon93,5160 00For

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

4. To elect our three Class II director nominees, Vera Imper, Ph.D., Glenn P. Muir, and Ming Yan, Ph.D., each to serve a three-year term expiring at our 2029 annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation, or removal: Ming Yan, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%
FOR: 76,741,063WITHHELD: 8,752,390

Cytek Biosciences, Inc.’s own tally for this item (“Elect Director: Ming Yan, Ph.D.”): 76,741,063 for, 8,752,390 withheld, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 129,142,587 outstanding shares: 59% for, 7% withheld (66% of the company cast a for/withheld vote).

The 57 asset managers below cast 100% of the shares they voted on this item FOR (31,527,416 for, 0 against).

FOR 89%11%
FOR: 31,527,416 (89.5%)ABSTAIN: 3,707,084 (10.5%)
Largest asset managers voting on “To elect our three Class II director nominees, Vera Imper, Ph.D., Glenn P. Muir, and Ming Yan, Ph.D., each to ” at Cytek Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock12,354,6590 00For
Vanguard7,284,7480 33,4510For
Fidelity2,553,6040 00For
TRUST FOR PROFESSIONAL MANAGERS00 2,017,8470Abstain
Royce1,628,0950 00For
State Street1,212,2520 1,5100For
Brown Capital Management Mutual Funds973,7070 00For
Charles Schwab911,2030 00For
Goldman Sachs845,0790 00For
RBB FUND, INC.00 801,2190Abstain
Dimensional00 785,1500Abstain
Russell Investments597,7860 00For
Equitable283,0940 00For
American Century281,5780 00For
TIAA242,3550 00For
QUANTITATIVE MASTER SERIES LLC199,1550 00For
Jackson National166,6890 28,1200For
Columbia Threadneedle167,5570 00For
Lincoln Financial157,8310 9,2760For
JPMorgan157,6210 00For
Invesco151,3810 00For
Voya134,5980 00For
Prudential/PGIM96,2570 13,2950For
AIG/SunAmerica95,5720 00For
BNY Mellon93,5160 00For

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

5. To elect our three Class II director nominees, Vera Imper, Ph.D., Glenn P. Muir, and Ming Yan, Ph.D., each to serve a three-year term expiring at our 2029 annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation, or removal: Vera Imper, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

76% Majority: yes · of votes cast

FOR 76%WITHHELD 24%
FOR: 64,769,976WITHHELD: 20,723,477

Cytek Biosciences, Inc.’s own tally for this item (“Elect Director: Vera Imper, Ph.D.”): 64,769,976 for, 20,723,477 withheld, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 129,142,587 outstanding shares: 50.2% for, 16% withheld (66% of the company cast a for/withheld vote).

The 57 asset managers below cast 100% of the shares they voted on this item FOR (28,289,297 for, 0 against).

FOR 80%ABSTAIN 20%
FOR: 28,289,297 (80.3%)ABSTAIN: 6,945,203 (19.7%)
Largest asset managers voting on “To elect our three Class II director nominees, Vera Imper, Ph.D., Glenn P. Muir, and Ming Yan, Ph.D., each to ” at Cytek Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock12,354,6590 00For
Vanguard7,267,0020 51,1960For
Fidelity2,553,5040 1000For
TRUST FOR PROFESSIONAL MANAGERS00 2,017,8470Abstain
Royce1,628,0950 00For
State Street1,210,7500 3,0120For
Brown Capital Management Mutual Funds00 973,7070Abstain
Charles Schwab911,2030 00For
Goldman Sachs845,0790 00For
RBB FUND, INC.00 801,2190Abstain
Dimensional00 785,1500Abstain
Russell Investments00 597,7860Abstain
Equitable170,7880 112,3060For
American Century00 281,5780Abstain
TIAA242,3550 00For
QUANTITATIVE MASTER SERIES LLC199,1550 00For
Jackson National00 194,8090Abstain
Columbia Threadneedle167,5570 00For
Lincoln Financial82,0000 85,1070Abstain
JPMorgan157,6210 00For
Invesco151,3810 00For
Voya00 134,5980Abstain
Prudential/PGIM96,2570 13,2950For
AIG/SunAmerica00 95,5720Abstain
BNY Mellon00 93,5160Abstain

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

Largest Cytek Biosciences, Inc. shareholders voting in 2025-2026

Ranked by the number of Cytek Biosciences, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 129,142,587 shares outstanding at the time of that meeting.

Top Cytek Biosciences, Inc. shareholders by shares voted, 2025-2026
#Asset manager % of shares outstanding
1BlackRock 12.55%
2Vanguard 6.27%
3Topline Capital Management, LLC 5.53%
4HHLR ADVISORS, LTD. 5.15%
5Boston Partners 4.39%
6State Street 2.63%
7GEODE CAPITAL MANAGEMENT, LLC 2.15%
8Fidelity 2.13%
9TRUST FOR PROFESSIONAL MANAGERS 1.56%
10Charles Schwab 1.56%

Reported Cytek Biosciences, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Cytek Biosciences, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder % outstanding Disclosure
BlackRock 13.17% 13F
Entities affiliated with BlackRock, Inc. 12.80% DEF14A
Entities affiliated with The Vanguard Group 6.01% DEF14A
Boston Partners 5.91% 13G
Vanguard Group 5.79% 13F
Entities affiliated with Topline Capital Partners, LP 5.25% DEF14A
Wenbin Jiang, Ph.D. 5.24% DEF14A
Entities affiliated with Hillhouse Investment Management, Ltd. 5.15% DEF14A
Millennium Management 4.87% 13F
Ming Yan, Ph.D. 4.17% DEF14A

Percentages above are of 129,142,587 shares outstanding, as reported by Cytek Biosciences, Inc. on its Form 10-Q dated 2026-04-30 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Cytek Biosciences, Inc.’s 10-Q dated 2026-04-30. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At Cytek Biosciences, Inc.'s shareholder meeting held 2026-06-10, in the 2025-2026 proxy season, 177 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,236 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of our named executive officers… — the proposal passed with 99.2% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Cytek Biosciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-16.

Cytek Biosciences, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).